SCHEMBL23601614

SCHEMBL23601614

COCCN(C)c1ccc(-c2cccc(N(C)c3nc4nncn4c4cc(Cl)ccc34)c2)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADK P55263 1/20 0.36
CFTR P13569 2/20 0.35
DGAT1 O75907 4/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
MAT2A P31153 3/20 0.32
PIK3CA P42336 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
PRMT5 O14744 2/20 0.31
MAPK8 P45983 1/20 0.31
CYP1A2 P05177 1/20 0.31
ACHE P22303 1/20 0.31
CYP3A4 P08684 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31229464 0.88 NPC1 (0.38) ADKFNTAFNTBMAT2AGRIN1
SCHEMBL23601442 0.88 NPC1 (0.38) ADKFNTAFNTBMAT2AGRIN1
SCHEMBL31229686 0.85 KDR (0.39) FNTAFNTBCYP1A2CYP3A4
SCHEMBL23601031 0.85 KDR (0.39) FNTAFNTBCYP1A2CYP3A4
SCHEMBL23577995 0.84 FNTA (0.37) FNTAFNTBMAT2APRMT5CYP1A2
SCHEMBL29909557 0.84 FNTA (0.37) FNTAFNTBMAT2AGRIN2BPRMT5
SCHEMBL23576895 0.84 FNTA (0.37) FNTAFNTBMAT2AGRIN2BPRMT5
SCHEMBL23601623 0.83 ACHE (0.43) MAT2AACHEKDM4EHTT
SCHEMBL23601235 0.83 FNTA (0.40) FNTAFNTBMAT2APRMT5CYP1A2
SCHEMBL29909768 0.83 FNTA (0.40) FNTAFNTBMAT2APRMT5CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ADK 72/4885CFTR 3469/4885DGAT1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.